Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor–positive breast cancer. The combination therapy demonstrates improved overall survival with tolerable safety profile, showing grade 3 adverse events in 15.1% of patients.etronomic Capecitabine Plus Aromatase Inhibitor Boosts Survival in HR+ Breast Cancer

“We propose that the metronomic chemo-ET combination could be a first-line option for patients who cannot tolerate CDK4/6 inhibitors or in resource-constrained settings due to the economic benefits of metronomic capecitabine. The efficacy of this combination after a CDK4/6 inhibitor treatment remains unknown and warrants further investigation,” the authors of the study wrote.

This study was led by Ruo-Xi Hong, MD, Sun Yat-sen University Cancer Center in Guangzhou, China. It was published online on January 2 in Journal of Clinical Oncology.

Source: MEDspace